Incyte (INCY) Downgraded by BidaskClub

BidaskClub downgraded shares of Incyte (NASDAQ:INCY) from a sell rating to a strong sell rating in a research note released on Thursday morning.

A number of other equities research analysts have also recently weighed in on INCY. Jefferies Group restated a buy rating on shares of Incyte in a research note on Friday, October 6th. Goldman Sachs Group initiated coverage on Incyte in a research note on Friday, October 6th. They set a buy rating and a $160.00 price objective for the company. JPMorgan Chase & Co. restated a buy rating on shares of Incyte in a research note on Wednesday, October 25th. BMO Capital Markets decreased their price objective on Incyte from $163.00 to $162.00 and set an outperform rating for the company in a research note on Thursday, October 26th. Finally, Oppenheimer set a $135.00 price objective on Incyte and gave the stock a hold rating in a research note on Tuesday, October 31st. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $143.25.

Incyte (NASDAQ:INCY) opened at $85.92 on Thursday. Incyte has a 12-month low of $85.75 and a 12-month high of $153.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.81 and a current ratio of 4.82. The stock has a market capitalization of $18,132.30, a price-to-earnings ratio of -107.40 and a beta of 0.59.

In other Incyte news, EVP Vijay K. Iyengar sold 5,000 shares of the stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $97.26, for a total value of $486,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Paul A. Friedman sold 28,507 shares of the stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $105.24, for a total value of $3,000,076.68. The disclosure for this sale can be found here. Over the last quarter, insiders sold 40,963 shares of company stock valued at $4,222,953. 17.70% of the stock is currently owned by company insiders.

Large investors have recently made changes to their positions in the company. Inverness Counsel LLC NY purchased a new position in shares of Incyte in the third quarter worth about $330,000. LMR Partners LLP purchased a new position in shares of Incyte in the third quarter worth about $394,000. Swiss National Bank raised its stake in shares of Incyte by 3.0% in the third quarter. Swiss National Bank now owns 641,700 shares of the biopharmaceutical company’s stock worth $74,912,000 after purchasing an additional 18,700 shares during the last quarter. Matrix Capital Management Company LP raised its stake in shares of Incyte by 28.3% in the second quarter. Matrix Capital Management Company LP now owns 1,796,716 shares of the biopharmaceutical company’s stock worth $226,225,000 after purchasing an additional 396,716 shares during the last quarter. Finally, Prudential Financial Inc. raised its stake in shares of Incyte by 0.6% in the third quarter. Prudential Financial Inc. now owns 236,699 shares of the biopharmaceutical company’s stock worth $27,633,000 after purchasing an additional 1,490 shares during the last quarter. Hedge funds and other institutional investors own 90.81% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Incyte (INCY) Downgraded by BidaskClub” was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://sportsperspectives.com/2018/02/04/incyte-incy-downgraded-by-bidaskclub.html.

About Incyte

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Analyst Recommendations for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply